Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Waldenström macroglobulinemia and relationship to immune deficiency.
Levy A, Guidez S, Debiais C, Princet I, Bouyer S, Dindinaud E, Delwail V, Systchenko T, Moya N, Gruchet C, Sabirou F, Bobin A, Gardeney H, Nsiala L, Cailly L, Olivier G, Motard C, Fleck E, Corby A, Roul C, Denis G, Dieval C, Leleu X, Tomowiak C. Levy A, et al. Among authors: guidez s. Leuk Lymphoma. 2021 Nov;62(11):2665-2670. doi: 10.1080/10428194.2021.1907379. Epub 2021 Jun 4. Leuk Lymphoma. 2021. PMID: 34085595 Review.
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
Al Tabaa Y, Casasnovas RO, Baillet C, Bachy E, Nicolas-Virelizier E, Schiano De Colella JM, Bailly C, Kanoun S, Guidez S, Gyan E, Gressin R, Morineau N, Ysebaert L, Le Gouill S, Tilly H, Houot R, Morschhauser F, Cartron G, Herbaux C. Al Tabaa Y, et al. Among authors: guidez s. Blood Adv. 2023 Jul 25;7(14):3735-3738. doi: 10.1182/bloodadvances.2023009911. Blood Adv. 2023. PMID: 37067945 Free PMC article. No abstract available.
Lenalidomide is safe and active in Waldenström macroglobulinemia.
Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, Salles G, Leblond V, Leleu X. Fouquet G, et al. Among authors: guidez s. Am J Hematol. 2015 Nov;90(11):1055-9. doi: 10.1002/ajh.24175. Epub 2015 Oct 6. Am J Hematol. 2015. PMID: 26284823 Free article. Clinical Trial.
IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.
Boyle E, Manier S, Lejeune J, Fouquet G, Guidez S, Bonnet S, Debarri H, Demarquette H, Dulery R, Gay J, Hennache B, Onraed B, Faucompré JL, Schraen S, Facon T, Avet-Loiseau H, Chevret S, Leblond V, Harding S, Leleu X. Boyle E, et al. Among authors: guidez s. Clin Cancer Res. 2016 Oct 15;22(20):5152-5158. doi: 10.1158/1078-0432.CCR-15-2899. Epub 2016 May 11. Clin Cancer Res. 2016. PMID: 27169996
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.
Fouquet G, Snell KI, Guidez S, Schraen S, Boyle E, Renaud L, Desmier D, Machet A, Moya N, Systchenko T, Gruchet C, Decaux O, Arnulf B, Fohrer C, Richez V, Kolb B, Macro M, Karlin L, Royer B, Pegourie B, Hebraud B, Caillot D, Perrot A, Moreau P, Facon T, Avet-Loiseau H, Dejoie T, Hulin C, Harding S, Leleu X. Fouquet G, et al. Among authors: guidez s. Leuk Lymphoma. 2018 Mar;59(3):583-589. doi: 10.1080/10428194.2017.1339876. Epub 2017 Jul 12. Leuk Lymphoma. 2018. PMID: 28697637
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia.
Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, Geffroy S, Sebda S, Nibourel O, Nudel M, Herbaux C, Renaud L, Tomowiak C, Guidez S, Tricot S, Roche-Lestienne C, Quesnel B, Preudhomme C, Leleu X. Poulain S, et al. Among authors: guidez s. Clin Cancer Res. 2017 Oct 15;23(20):6325-6335. doi: 10.1158/1078-0432.CCR-17-0007. Epub 2017 Jul 28. Clin Cancer Res. 2017. PMID: 28754818
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X. Fouquet G, et al. Among authors: guidez s. Oncotarget. 2018 May 8;9(35):23890-23899. doi: 10.18632/oncotarget.25156. eCollection 2018 May 8. Oncotarget. 2018. PMID: 29844860 Free PMC article.
Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.
Richez V, Gruchet C, Guidez S, Fouquet G, Azais I, Durand G, Javaugue V, Brigaud A, Plasse F, Diolez J, Machet A, Moya N, Gardeney H, Franques P, Bobin A, Levy A, Sabirou F, Bonnin A, Dieval C, Primault S, Barrier J, Fleck E, Bouyier S, Daras C, Princet I, Bauwens D, Legros L, Fuzibet JG, Gil A, Bridoux F, Avet-Loiseau H, Leleu X. Richez V, et al. Among authors: guidez s. Am J Hematol. 2019 Jan;94(1):E17-E20. doi: 10.1002/ajh.25327. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30358902 Free article. No abstract available.
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Guidez S, Labreuche J, Drumez E, Ysebaert L, Bakala J, Delette C, Hivert B, Protin C, Declercq H, Verlay M, Marolleau JP, Duhamel A, Morel P; French Innovative Leukemia Organization (FILO) CLL group. Guidez S, et al. Blood Adv. 2018 Nov 27;2(22):3102-3111. doi: 10.1182/bloodadvances.2018021287. Blood Adv. 2018. PMID: 30455359 Free PMC article.
52 results